According to the NCI website, Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells.
Indikationen/Anwendungsmöglichkeiten gemäss Chemocare.com:
Nilutamide therapy is for men with advanced prostate cancer at stage D2, when there is evidence of metastases (cancer spread) to other areas of the body.
Anti-androgen medications are usually given in conjunction with LHRH agonists or after orchiectomy (surgical removal of the testicles).
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link to Physicians Desk Reference (PDR)
Info for Patients presented by Scott Hamilton from Chemocare.com